Risk of gastrointestinal perforation in cancer patients receiving ramucirumab: a meta-analysis of randomized controlled trials.
Wang, Zexing
Risk of gastrointestinal perforation in cancer patients receiving ramucirumab: a meta-analysis of randomized controlled trials. [electronic resource] - Journal of chemotherapy (Florence, Italy) Aug 2016 - 328-34 p. digital
Publication Type: Journal Article; Meta-Analysis
1973-9478
10.1179/1973947815Y.0000000053 doi
Antibodies, Monoclonal--adverse effects
Antibodies, Monoclonal, Humanized
Antineoplastic Agents--adverse effects
Gastrointestinal Diseases--chemically induced
Humans
Incidence
Intestinal Perforation--chemically induced
Randomized Controlled Trials as Topic
Risk
Ramucirumab
Risk of gastrointestinal perforation in cancer patients receiving ramucirumab: a meta-analysis of randomized controlled trials. [electronic resource] - Journal of chemotherapy (Florence, Italy) Aug 2016 - 328-34 p. digital
Publication Type: Journal Article; Meta-Analysis
1973-9478
10.1179/1973947815Y.0000000053 doi
Antibodies, Monoclonal--adverse effects
Antibodies, Monoclonal, Humanized
Antineoplastic Agents--adverse effects
Gastrointestinal Diseases--chemically induced
Humans
Incidence
Intestinal Perforation--chemically induced
Randomized Controlled Trials as Topic
Risk
Ramucirumab